Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well bortezomib works in treating patients with
hepatocellular carcinoma (liver cancer) that cannot be removed with surgery. Bortezomib may
stop the growth of tumor cells by blocking the enzymes necessary for their growth.